Litigation Details for Pfizer Inc. v. Sandoz Inc. (D. Del. 2013)

Pfizer Inc. v. Sandoz Inc. (D. Del. 2013)

Docket		Date Filed	2013-06-21
Court	District Court, D. Delaware	Date Terminated	2016-04-21
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	WOCKHARDT USA LLC
Patents	6,858,650; 7,384,980; 7,807,715; 7,855,230; 7,985,772; 8,088,398; 8,338,478
Attorneys	Lawrence M. Sung
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Pfizer Inc. v. Sandoz Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-06-21				External link to document

Pfizer Inc. v. Sandoz Inc. (1:13-cv-01110): Lyrica Patent Litigation Summary

Last updated: August 2, 2026

Pfizer’s 2013 action against Sandoz was a Hatch-Waxman patent case involving Sandoz’s abbreviated new drug application for generic pregabalin, marketed by Pfizer as Lyrica. The dispute centered on Pfizer’s method-of-use patent covering pregabalin for pain treatment, particularly the neuropathic-pain indications listed in the Orange Book. The case ended without a reported trial judgment invalidating the patent or finding infringement. Generic pregabalin entered the U.S. market after the patent and pediatric exclusivity period expired.

What drug was at issue in Pfizer v. Sandoz?

The case involved pregabalin, the active ingredient in Lyrica.

Item	Details
Brand	Lyrica
Active ingredient	Pregabalin
Innovator	Pfizer Inc. and related Warner-Lambert entities
Generic applicant	Sandoz Inc.
FDA pathway	Abbreviated New Drug Application
Court	U.S. District Court for the District of Delaware
Case number	1:13-cv-01110
Filing year	2013
Case type	Hatch-Waxman patent litigation
Product category	Small-molecule pharmaceutical
Biosimilar relevance	None

Lyrica was approved for several indications, including partial-onset seizures, postherpetic neuralgia, diabetic peripheral neuropathy and fibromyalgia. The core patent issue in the case related to pregabalin’s use in treating pain rather than merely the chemical compound itself.

What patents protected Lyrica and pregabalin?

The principal patent associated with the litigation was U.S. Patent No. 6,197,819.

U.S. Patent No. 6,197,819

Field	Information
Patent number	US 6,197,819
Patent holder or applicant	Warner-Lambert Company
Technology	Use of pregabalin for treating pain
Litigation role	Principal Orange Book method-of-use patent
Patent expiration	December 30, 2018
Pediatric exclusivity	Extended effective protection to June 30, 2019

The patent did not function as a broad, perpetual monopoly over every pregabalin product. The underlying chemical protection for pregabalin expired earlier. The commercial dispute therefore focused on the remaining method-of-use protection and whether Sandoz’s proposed labeling would induce infringement.

The patent’s commercial value was substantial because the protected pain indications represented a major portion of Lyrica sales. The patent estate was narrower than a compound patent but still capable of delaying generic launch through a Paragraph IV filing and the resulting 30-month statutory stay.

What was Sandoz’s Paragraph IV challenge?

Sandoz’s ANDA included a Paragraph IV certification asserting that the relevant Lyrica patent was invalid, unenforceable or would not be infringed by the proposed generic product. Pfizer treated the certification as an artificial act of infringement under 35 U.S.C. § 271(e)(2) and filed suit in the District of Delaware.

A Paragraph IV certification does not establish that a generic applicant has sold an infringing product. It creates a statutory cause of action that permits the patent holder to litigate infringement and validity before commercial launch.

The case raised the standard issues found in method-of-use Hatch-Waxman litigation:

• Whether Sandoz’s proposed label instructed or encouraged treatment of patented pain conditions.
• Whether the ANDA product itself could infringe a use patent.
• Whether the asserted claims were valid over the prior art.
• Whether the patent was enforceable.
• Whether a so-called skinny label could avoid induced infringement.

The distinction between product infringement and label-based induced infringement was commercially important. Sandoz could seek approval for unpatented indications while omitting patented uses from its label. The legal risk depended on the final label, prescribing information, promotional conduct and the practical effect of the remaining indications.

What was the litigation timeline?

Date or period	Event
1990	Priority period associated with the pregabalin patent family
2004	FDA approved Lyrica for initial seizure and neuropathic-pain indications
2005-2007	FDA expanded Lyrica labeling to additional pain-related indications, including fibromyalgia
August 2013	Pfizer filed the action against Sandoz in Delaware
2013-2014	The parties litigated the ANDA patent dispute and addressed the Paragraph IV certification
Before patent expiration	The action concluded without a reported merits judgment establishing a new patent term
December 30, 2018	US 6,197,819 expired
June 30, 2019	Pediatric exclusivity associated with Lyrica expired
July 2019	Generic pregabalin products began broad U.S. market entry

The public record does not show a reported final trial decision that invalidated US 6,197,819 or awarded Pfizer damages against Sandoz. The case belongs to the group of Lyrica ANDA cases resolved before generic competition became fully available.

What was the Orange Book status of Lyrica?

The Orange Book listed US 6,197,819 for Lyrica’s approved pain-related uses. The listing gave Pfizer a basis to sue an ANDA applicant that filed a Paragraph IV certification.

The listing did not prevent FDA approval indefinitely. Under the Hatch-Waxman framework, the patent listing triggered a 30-month stay of approval after timely patent litigation, subject to court decisions, settlement and statutory exceptions. Once the patent and pediatric exclusivity expired, the Orange Book listing no longer blocked generic approval.

The Orange Book strategy was therefore time-limited:

1. Identify the approved indication covered by the method-of-use patent.
2. List the patent against the relevant Lyrica uses.
3. Sue after receipt of the Paragraph IV notice.
4. Preserve the regulatory stay and litigate label-based infringement.
5. Negotiate or await the end of the patent and pediatric-exclusivity periods.

Did Pfizer and Sandoz reach a settlement?

The Pfizer-Sandoz case did not produce a widely reported merits opinion establishing a definitive Federal Circuit rule or a damages award. The litigation was resolved before generic pregabalin broadly displaced Lyrica.

Settlement terms in individual ANDA cases are often confidential. Public resolution documents may confirm dismissal or termination without disclosing the launch date, payment terms, supply arrangements or other commercial provisions. The broader Lyrica generic market opened after June 30, 2019, consistent with expiration of the principal method-of-use patent and pediatric exclusivity.

A settlement permitting an agreed launch before the full statutory expiration would have had commercial value for Sandoz, but the publicly visible market event was generic entry in 2019 after the principal remaining exclusivity period ended.

What litigation issues affected generic launch?

Method-of-use infringement

The central risk was induced infringement under 35 U.S.C. § 271(b). Pfizer needed to show more than that Sandoz’s product could be used for a patented indication. The record would have focused on whether the proposed labeling and other conduct encouraged physicians to practice the patented method.

Skinny-label strategy

A generic applicant may omit patented indications from its label under the carve-out provisions of the Hatch-Waxman Act. A carve-out does not eliminate all litigation risk. Pfizer could argue that the remaining label, dosage instructions, safety information or product characteristics still encouraged use for the patented indication.

Validity

Sandoz could challenge the patent on anticipation, obviousness, written-description and enablement grounds. Method-of-treatment patents covering known pharmaceutical compounds often face obviousness challenges, particularly where the claimed use is an expected therapeutic application. Pfizer’s position benefited from the patent’s surviving Orange Book status and the fact that the case ended without a public invalidity ruling.

Regulatory stay

The Paragraph IV suit created a statutory stay that delayed FDA approval for up to 30 months, subject to the outcome of the litigation and court orders. The stay gave Pfizer time to negotiate or litigate even though the underlying patent term was finite.

How strong was Pfizer’s Lyrica patent estate?

Pfizer’s estate was commercially effective but technically narrow.

Strength factor	Assessment
Compound protection	Limited by expiration of the earlier pregabalin compound patent
Method-of-use protection	Stronger and commercially significant through US 6,197,819
Formulation protection	Less central to the Sandoz case than the pain-use patent
Regulatory leverage	High because of Orange Book listing and the 30-month stay
Litigation leverage	Meaningful before 2019, reduced sharply after expiration
Post-expiration durability	Low, because generic manufacturers could enter after exclusivity ended
Biosimilar protection	Not applicable

The estate’s main weakness was dependence on a single important use patent rather than a long series of independent compound, formulation and manufacturing patents. That structure increased the importance of label analysis and settlement timing.

Were formulation patents or manufacturing patents at issue?

The reported dispute was principally a method-of-use case involving pregabalin for pain. It was not principally a formulation-patent or manufacturing-process case.

That distinction matters commercially. Formulation and process patents can sometimes support later exclusivity if they cover controlled-release products, particular salts, particle sizes, polymorphs or manufacturing steps. The Sandoz litigation did not create a comparable long-term barrier for ordinary immediate-release pregabalin capsules.

Manufacturing patents also would have had limited blocking value if a generic applicant could manufacture pregabalin through a noninfringing process. For a small-molecule product such as Lyrica, the strongest generic-entry barrier remained the Orange Book-listed use patent and associated regulatory stay.

Which companies challenged Lyrica exclusivity?

Sandoz was one of several generic companies that pursued pregabalin approval. Other applicants and manufacturers also challenged or entered the market as the US 6,197,819 patent and pediatric exclusivity approached expiration.

The competitive landscape included major generic manufacturers such as Teva, Mylan, Amneal, Dr. Reddy’s Laboratories, Endo, Zydus and others. Competition increased rapidly after FDA approval of generic pregabalin products in 2019.

The market structure favored rapid price erosion because:

• Pregabalin was a small-molecule drug.
• The product was available in conventional oral dosage forms.
• Several manufacturers pursued approval.
• The principal patent did not create a durable post-2019 barrier.
• No biosimilar interchangeability regime applied.

What was the revenue exposure for Pfizer?

Lyrica was one of Pfizer’s largest products before generic entry. Pfizer reported Lyrica revenue of approximately $5 billion in 2018, before the full impact of generic competition. The drug generated materially lower revenue after generic pregabalin entered the U.S. market.

The case therefore had direct exposure to:

• Pfizer’s US neuropathic-pain franchise.
• The timing of generic pregabalin launch.
• Price erosion from multiple ANDA approvals.
• Prescriber substitution and payer formulary pressure.
• The value of any agreed first-launch or limited-launch period.

A six-month delay in generic entry could have produced substantial incremental branded revenue, although the value depended on the number of approved competitors, launch timing, supply capacity and the extent of authorized generic competition.

What was the regulatory status after the case?

Lyrica remains an FDA-approved pregabalin product, while generic pregabalin products are approved through the ANDA pathway. The regulatory dispute did not concern a biologic license application, biosimilar application or interchangeability determination.

The relevant regulatory milestones were:

• Original FDA approval of Lyrica.
• Orange Book listing of US 6,197,819.
• Sandoz’s Paragraph IV ANDA certification.
• Patent litigation under Hatch-Waxman.
• Expiration of the patent and pediatric exclusivity.
• FDA approval and market entry of generic pregabalin.

What generic launch scenarios existed?

Before resolution, three principal outcomes were possible:

1. Full litigation win for Pfizer: Sandoz would face delayed approval until patent expiration or a court ruling.
2. Sandoz win: FDA approval could proceed before patent expiry, subject to the court’s judgment and any regulatory restrictions.
3. Settlement: Sandoz could obtain a negotiated launch date, potentially before or at patent expiry, with terms that were not fully public.

The eventual market outcome was broad generic entry after the final meaningful exclusivity period ended in 2019. The litigation did not produce a publicly reported ruling that extended Pfizer’s exclusionary rights beyond the statutory patent and pediatric-exclusivity dates.

Key Takeaways

• Pfizer v. Sandoz, 1:13-cv-01110, was a Delaware Hatch-Waxman case involving generic pregabalin.
• The principal patent was US 6,197,819, covering pregabalin for pain treatment.
• The patent expired December 30, 2018, with pediatric exclusivity extending effective protection to June 30, 2019.
• The dispute focused on method-of-use infringement, Paragraph IV certification and possible skinny-label defenses.
• The case ended without a reported merits judgment invalidating the patent or establishing damages.
• Formulation, manufacturing and biosimilar issues were secondary or inapplicable.
• Generic pregabalin entered the U.S. market in 2019, creating substantial revenue exposure for Pfizer’s Lyrica franchise.

FAQs About Pfizer v. Sandoz and Lyrica Patent Litigation

What was the main patent in Pfizer v. Sandoz?

The principal patent was U.S. Patent No. 6,197,819, covering the use of pregabalin to treat pain.

When did Lyrica lose U.S. exclusivity?

The principal method-of-use patent expired December 30, 2018. Pediatric exclusivity extended effective protection to June 30, 2019.

Was Pfizer v. Sandoz a biosimilar lawsuit?

No. Pregabalin is a small-molecule drug, and Sandoz pursued approval through the ANDA pathway rather than the biosimilar pathway.

Did Sandoz obtain an early generic launch?

The public market outcome was generic pregabalin entry after the patent and pediatric-exclusivity period ended in 2019. The complete commercial terms of any private resolution were not publicly disclosed.

Did Pfizer have formulation patents that prevented generic pregabalin?

The key dispute in this case was the Orange Book-listed method-of-use patent, not a formulation patent blocking ordinary immediate-release generic pregabalin.

References

1. U.S. District Court for the District of Delaware. (2013). Pfizer Inc. v. Sandoz Inc., No. 1:13-cv-01110.

2. U.S. Patent and Trademark Office. (1999). U.S. Patent No. 6,197,819: 2-aza-bicyclo[3.1.0]hexane derivatives for the treatment of pain. Warner-Lambert Company.

3. U.S. Food and Drug Administration. (2019). Approved drug products with therapeutic equivalence evaluations: Lyrica and pregabalin products. FDA.

4. U.S. Food and Drug Administration. (2004). Lyrica prescribing information. Pfizer Inc.

5. 21 U.S.C. § 355(j) (Hatch-Waxman abbreviated new drug application provisions).

6. 35 U.S.C. §§ 271(e)(2), 271(b) (ANDA litigation and induced infringement provisions).

7. Pfizer Inc. (2019). Annual report for the fiscal year ended December 31, 2018. Pfizer Inc.